编程死亡1抑制剂与放射治疗相结合降低了乳腺癌中的表皮生长因子受体表达
1School of Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu Province, China. njzyydx_wuyou@163.com.
Hereditas
|August 16, 2025
概括
编程死亡1 (PD-1) 抑制剂与放射治疗相结合,有效降低乳腺癌 (BC) 患者表皮生长因子受体 (EGFR) 表达. 这种组合疗法也显著改善了患者的预后和无进展生存率.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 辐射瘤学 辐射瘤学
背景情况:
- 乳腺癌 (BC) 仍然是一个重大的健康问题.
- 了解影响BC治疗反应的分子机制至关重要.
- 需要新的治疗策略来改善患者的治疗结果.
研究的目的:
- 评估编程死亡1 (PD-1) 抑制剂和放射治疗对乳腺癌中P53和表皮生长因子受体 (EGFR) 表达的联合作用.
- 评估这种联合治疗对乳腺癌患者预后的影响.
主要方法:
- 从2022年4月至2023年4月期间接受治疗的104名乳腺癌患者的临床数据的回顾性分析.
- 在瘤组织中测量P53和EGFR表达水平.
- 对患者生存时间和并发症的随访.
主要成果:
- 与对照组相比,联合PD-1抑制剂和放射治疗显著降低了EGFR表达.
- 在联合治疗组中,无进展生存时间 (PFS) 的中位数显着更长.
- 治疗前的EGFR水平被确定为预后的独立风险因素,较低的水平与更好的PFS相关.
结论:
- PD-1 抑制剂加放射治疗是抑制乳腺癌EGFR表达的有效策略.
- 这种组合疗法在改善乳腺癌患者的预后方面具有明显的益处.
更多相关视频
08:26Live Imaging of Drug Responses in the Tumor Microenvironment in Mouse Models of Breast Cancer
Published on: March 24, 2013
25.1K
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.8K
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle
6.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.7K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
